Clinical Trial Update: A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of Otelixizumab in Graves Ophthalmopathy was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• Otelixizumab (otelixizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Graves Ophthalmopathy | Phase 2 | Status: TERMINATED | Results posted: 2017-08-03